semaglutide cardiovascular outcomes news 2025 october A Lancet analysis of the SELECT trial concluded that reduced major adverse events by 20% in adults with overweight or obesity, regardless of how much weight patients actually lost Semaglutide and Cardiovascular Outcomes in

The primary global semaglutide market trend is that the drug offers substantial weight loss, improved glycemic control, and is the preferred therapy

Ann Clin Biochem (2015) 52(Pt 1):1838

Choosing the right medication depends on your health history, other medical conditions, and how well you tolerate potential side effects

A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo

Although stopping Ozempic and weight gain are certainly related to one another, those who choose to gradually lower the doses will be much less likely to experience any serious withdrawal symptoms